LONDON, Sept 23- West African nations hit by the Ebola virus epidemic will need international help to rebuild for years to come and it is time for mining companies and business to get involved, the head of the African Development Bank said on Tuesday.» Read More
What's $23 between friends, er, sparring business partners? The question brings back memories of my grandfather who was of the generation that would hold a grudge for years against a distant relative who still owed him a small amount of money.
I've been trying for years to get an interview with Genentech CEO Art Levinson. As far as I know, he's never done a TV chat. Every time I've asked the answer has come back no. I've gotten pretty good access to other execs, but never the top dog.
Shares of Swiss drugmaker Roche are trading significantly lower overseas and in over-the-counter activity here in the States after the company reported earnings.
Right around the closing bell today an FDA advisory committee voted unanimously in favor of recommending approval of Eli Lilly's bloodthinner called Effient.
Before Gardasil came to market two to three years ago, some analysts were saying it would become the biggest-selling vaccine in history. But hope and reality have turned out to be two different things.
Diabetes drugmaker Amylin Pharmaceuticals is headquartered in San Diego. Like a lot of companies, though, it's incorporated in Delaware. But, if a couple of major shareholders get their way, AMLN could reincorporate in an unlikely state.
So, what do you do at the end of a week where your company's stock was the worst performer in the Dow and you've got some bad news that could make the shares go down even more? You employ one of the oldest PR tricks in the book.
Genentech shares dropped three percent today or $2.85 to $81.24 after Roche showed some chutzpah and lowered its bid for DNA.
Pfizer is quitting the ad agency that tried to tell smokers it's their time to quit.
I need a break from blogging all-things Pfizer. Sequenom to the rescue with more data on its diagnostic test for Down Syndrome. Out of nearly 900 women there were no false negatives, but for the first time SQNM reported one false positive.
The editorial board of "The Wall Street Journal" weighs in today on the Pfizer-Wyeth deal. The opinion piece details all of the well-documented problems facing big pharma and—perhaps not surprisingly coming from the WSJ editorial page—blames Washington for many of them.
Reporters could only listen to Pfizer's hastily-organized "Investor Luncheon," so I can't tell you how many people showed up or what the room looked like. But Chairman and CEO Jeff Kindler drew a pretty good picture at the start of his opening remarks.
This is the first paragraph/short story.
As I've blogged before, it seems all of the major drug companies are falling all over each other to be the biggest, or at least the best "biopharma" firm in the world. But PFE and WYE are the first, as far as I know, to put it into a URL.
A few days into his term, President Obama appears to have begun to undo another Bush-era policy. He hasn't yet formally lifted the Bush-imposed ban on federal funding of new embryonic stem cell research, but Obama's Food and Drug Administration has already set the stage for it.
For years pharmaceutical companies and health authorities have been trying to crack down on counterfeit prescription drugs. But on a new United Kingdom website the world's biggest drug company, Pfizer, is apparently taking the fight against knockoffs to a whole nutha level.
Dr. Steven Nissen, the cardiology chief at the Cleveland Clinic, reportedly remains on the shortlist to possibly become the next FDA Commissioner. Some analysts believe if Dr. Nissen gets the nod there could be a negative knee-jerk reaction in the big pharma sector stocks.
Dow component and giant healthcare company--you really can't lump it in with big pharma because it sells drugs, medical devices and consumer products--Johnson & Johnson reported earnings this morning.
The JPMorgan Healthcare Conference typically frontloads the conference putting most, if not all, of the heavy hitters' presentations in the first couple of days of the four-day event. So, it's no surprise that a company the size of Dendreon was pulling up the rear. But that doesn't mean there wasn't any news.
Even though it's one of the leading causes of cancer death in the U.S., pancreatic normally doesn't get much attention.